Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wolfe Research Upgrades Roper Technologies to Outperform, Announces $480 Price Target

Wolfe Research analyst Nigel Coe upgrades Roper Technologies (NYSE:ROP) from Peer Perform to Outperform and announces $480 price target.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Wolfe Research analyst Nigel Coe upgrades Roper Technologies (NYSE:ROP) from Peer Perform to Outperform and announces $480 price target.

Truist Securities Maintains Buy on OrthoPediatrics, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 6:59 AM

Truist Securities maintains OrthoPediatrics (NASDAQ:KIDS) with a Buy and lowers the price target from $78 to $75.

KIDS

FDA
News

Insmed Incorporated Study Titled ‘A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 6:59 AM

https://clinicaltrials.gov/ct2/show/NCT05090904

INSM

Nuvei Partners With Wix To Process Payments

By Benzinga Newsdesk

Today, 6:59 AM

Nuvei Corporation ("Nuvei" or the "Company") (NASDAQ:NVEI) (TSX:NVEI), the global payment technology partner of thriving brands, today announced a partnership

NVEI

Analyst Ratings

Where S&P Global Stands With Analysts

By Benzinga Insights

Today, 6:59 AM

S&P Global (NYSE:SPGI) has observed the following analyst ratings within the last quarter:

SPGI

Wolfe Research Upgrades Roper Technologies to Outperform, Announces $480 Price Target

Related Posts

Truist Securities Maintains Buy on OrthoPediatrics, Lowers Price Target to $75

Insmed Incorporated Study Titled ‘A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

Nuvei Partners With Wix To Process Payments

Where S&P Global Stands With Analysts